Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zadavotide guraxetan - Fusion Pharmaceuticals

Next Previous
Drug Profile

Zadavotide guraxetan - Fusion Pharmaceuticals

Alternative Names: 225Ac-PSMA I&T; Ac-PSMA I&T - Fusion Pharmaceuticals; Ac225-PSMA - Fusion Pharmaceuticals; AZD-2265; FPI-2265

Latest Information Update: 06 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RadioMedix
  • Developer Fusion Pharmaceuticals
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 03 Jun 2026 Phase-I/II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (IV) (NCT07590934)
  • 03 Jun 2026 Astrazeneca initiates enrolment in the phase I/II PROSPECTOR trial for Prostate cancer (Monotherapy, Hormone refractory, Metastatic disease, Second line therapy or greater) (NCT07590934)
  • 14 May 2026 AstraZeneca plans a phase I/II trial for Prostate cancer (Metastatic disease, Combination therapy, Second-line therapy or greater, Hormone-refractory) in USA, Australia, Germany, Italy, South Korea, Spain, United Kingdom (IV, Injection) in May 2026 (NCT07590934) (EudraCT2025-524920-23)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top